



## Safety Data Sheet

Copyright, 2026, 3M Company.

All rights reserved. Copying and/or downloading of this information for the purpose of properly utilizing 3M products is allowed provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from 3M, and (2) neither the copy nor the original is resold or otherwise distributed with the intention of earning a profit thereon.

|                        |           |                         |          |
|------------------------|-----------|-------------------------|----------|
| <b>Document Group:</b> | 20-7261-9 | <b>Version Number:</b>  | 8.01     |
| <b>Issue Date:</b>     | 07/17/26  | <b>Supersedes Date:</b> | 05/30/24 |

### SECTION 1: Identification

#### 1.1. Product identifier

3M™ Screen Printing UV Ink 9831 Transparent Orange

#### Product Identification Numbers

75-3470-6904-1  
7000056111

#### 1.2. Recommended use and restrictions on use

##### Recommended use

Screen Printing Ink, Ink

#### 1.3. Supplier's details

|                      |                                                 |
|----------------------|-------------------------------------------------|
| <b>MANUFACTURER:</b> | 3M                                              |
| <b>DIVISION:</b>     | Commercial Branding and Transportation Division |
| <b>ADDRESS:</b>      | 3M Center, St. Paul, MN 55144-1000, USA         |
| <b>Telephone:</b>    | 1-888-3M HELPS (1-888-364-3577)                 |

#### 1.4. Emergency telephone number

1-800-364-3577 or (651) 737-6501 (24 hours)

### SECTION 2: Hazard identification

#### 2.1. Hazard classification

Serious Eye Damage/Irritation: Category 2A.

Skin Sensitizer: Category 1.

Reproductive Toxicity: Category 1B.

Specific Target Organ Toxicity (repeated exposure): Category 1.

#### 2.2. Label elements

##### Signal word

Danger

##### Symbols

Exclamation mark | Health Hazard |

##### Pictograms

**Hazard Statements**

Causes serious eye irritation.

May cause an allergic skin reaction.

May damage fertility or the unborn child.

Causes damage to organs through prolonged or repeated exposure: respiratory system.

**Precautionary statements****Prevention:**

Obtain special instructions before use.

Do not handle until all safety precautions have been read and understood.

Do not breathe vapors.

Wash exposed skin thoroughly after handling.

Do not eat, drink or smoke when using this product.

Contaminated work clothing should not be allowed out of the workplace.

Wear protective gloves, eye protection, and if needed, respiratory protection (see SDS Section 8).

**Response:**

IF ON SKIN: Wash with plenty of soap and water.

IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

IF exposed or concerned: Get medical attention.

Get medical attention if you feel unwell.

If eye irritation persists or if skin irritation or rash occurs: Get medical attention.

Take off contaminated clothing and wash it before reuse.

**Storage:**

Store locked up.

**Disposal:**

Dispose of contents and container in accordance with applicable local, regional, national, and international regulations.

10% of the mixture consists of ingredients of unknown acute oral toxicity.

10% of the mixture consists of ingredients of unknown acute dermal toxicity.

**SECTION 3: Composition/information on ingredients**

| Ingredient                                                         | C.A.S. No.    | % by Wt                  |
|--------------------------------------------------------------------|---------------|--------------------------|
| PHENOXY ETHYL ACRYLATE                                             | 48145-04-6    | 15 - 40 Trade Secret *   |
| VINYLCAPROLACTAM                                                   | 2235-00-9     | 10 - 30 Trade Secret *   |
| METHACRYLATE POLYMER                                               | Trade Secret* | 10 - 20                  |
| ALIPHATIC URETHANE ACRYLATE                                        | Trade Secret* | 10 - 15                  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE | 4424-06-0     | 1 - 5                    |
| DIETHYLENE GLYCOL ETHYL ETHER                                      | 7328-17-8     | 0.5 - 1.5 Trade Secret * |

|                                                                                        |             |                          |
|----------------------------------------------------------------------------------------|-------------|--------------------------|
| ACRYLATE                                                                               |             |                          |
| 2-PHENOXYETHANOL                                                                       | 122-99-6    | 0.5 - 1.5 Trade Secret * |
| OCTAMETHYLCYCLOTETRASILOXANE                                                           | 556-67-2    | 0.1 - 1 Trade Secret *   |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-<br>PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL<br>ACRYLATE] | 52408-84-1  | 0.1 - 1 Trade Secret *   |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYLMETHYL)-2-(PHENYLMETHYL)-             | 119313-12-1 | 0.1 - 1 Trade Secret *   |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYLMETHYL)-                | 71868-10-5  | 0.1 - 1 Trade Secret *   |

\*The specific chemical identity and/or exact percentage (concentration) of this composition has been withheld as a trade secret.

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

#### Inhalation:

Remove person to fresh air. If you feel unwell, get medical attention.

#### Skin Contact:

Immediately wash with soap and water. Remove contaminated clothing and wash before reuse. If signs/symptoms develop, get medical attention.

#### Eye Contact:

Immediately flush with large amounts of water. Remove contact lenses if easy to do. Continue rinsing. Get medical attention.

#### If Swallowed:

Rinse mouth. If you feel unwell, get medical attention.

### 4.2. Most important symptoms and effects, both acute and delayed

Allergic skin reaction (redness, swelling, blistering, and itching). Target organ effects following prolonged or repeated exposure. See Section 11 for additional details.

### 4.3. Indication of any immediate medical attention and special treatment required

Not applicable

## SECTION 5: Fire-fighting measures

### 5.1. Suitable extinguishing media

In case of fire: Use a fire fighting agent suitable for ordinary combustible material such as water or foam to extinguish.

### 5.2. Special hazards arising from the substance or mixture

Closed containers exposed to heat from fire may build pressure and explode.

### Hazardous Decomposition or By-Products

#### Substance

Aldehydes  
Formaldehyde  
Carbon monoxide  
Carbon dioxide  
Oxides of Nitrogen

#### Condition

During Combustion  
During Combustion  
During Combustion  
During Combustion  
During Combustion

### 5.3. Special protective actions for fire-fighters

Water may not effectively extinguish fire; however, it should be used to keep fire-exposed containers and surfaces cool and prevent explosive rupture. Wear full protective clothing, including helmet, self-contained, positive pressure or pressure demand breathing apparatus, bunker coat and pants, bands around arms, waist and legs, face mask, and protective covering for exposed areas of the head.

## SECTION 6: Accidental release measures

### 6.1. Personal precautions, protective equipment and emergency procedures

Evacuate area. Ventilate the area with fresh air. For large spill, or spills in confined spaces, provide mechanical ventilation to disperse or exhaust vapors, in accordance with good industrial hygiene practice. Use personal protective equipment based on the results of an exposure assessment. Refer to Section 8 for PPE recommendations. If anticipated exposure resulting from an accidental release exceeds the protective capabilities of the PPE listed in Section 8, or are unknown, select PPE that offers an appropriate level of protection. Consider the physical and chemical hazards of the material when doing so. Examples of PPE ensembles for emergency response could include wearing bunker gear for a release of flammable material; wearing chemical protective clothing if the spilled material is a corrosive, a sensitizer, a significant dermal irritant, or can be absorbed through the skin; or donning a positive pressure supplied-air respirator for chemicals with inhalation hazards. For information regarding physical and health hazards, refer to sections 2 and 11 of the SDS.

### 6.2. Environmental precautions

Avoid release to the environment. For larger spills, cover drains and build dikes to prevent entry into sewer systems or bodies of water.

### 6.3. Methods and material for containment and cleaning up

Contain spill. Working from around the edges of the spill inward, cover with bentonite, vermiculite, or commercially available inorganic absorbent material. Mix in sufficient absorbent until it appears dry. Remember, adding an absorbent material does not remove a physical, health, or environmental hazard. Collect as much of the spilled material as possible. Place in a closed container approved for transportation by appropriate authorities. Clean up residue with an appropriate solvent selected by a qualified and authorized person. Ventilate the area with fresh air. Read and follow safety precautions on the solvent label and SDS. Seal the container. Dispose of collected material as soon as possible in accordance with applicable local/regional/national/international regulations.

## SECTION 7: Handling and storage

### 7.1. Precautions for safe handling

Do not handle until all safety precautions have been read and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Do not get in eyes, on skin, or on clothing. Do not eat, drink or smoke when using this product. Wash thoroughly after handling. Contaminated work clothing should not be allowed out of the workplace. Avoid release to the environment. Wash contaminated clothing before reuse. Avoid contact with oxidizing agents (eg. chlorine, chromic acid etc.) Use personal protective equipment (gloves, respirators, etc.) as required.

### 7.2. Conditions for safe storage including any incompatibilities

Store away from heat. Store away from oxidizing agents.

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

#### Occupational exposure limits

If a component is disclosed in section 3 but does not appear in the table below, an occupational exposure limit is not available for the component.

| Ingredient           | C.A.S. No. | Agency                  | Limit type                       | Additional Comments |
|----------------------|------------|-------------------------|----------------------------------|---------------------|
| VINYLCAPROLACTAM     | 2235-00-9  | Manufacturer determined | TWA(8 hours):0.1 ppm(0.57 mg/m3) |                     |
| OCTAMETHYLCYCLOTETRA | 556-67-2   | AIHA                    | TWA:10 ppm                       |                     |

## SILOXANE

ACGIH : American Conference of Governmental Industrial Hygienists  
 AIHA : American Industrial Hygiene Association  
 CMRG : Chemical Manufacturer's Recommended Guidelines  
 OSHA : United States Department of Labor - Occupational Safety and Health Administration  
 TWA: Time-Weighted-Average  
 STEL: Short Term Exposure Limit  
 CEIL: Ceiling

## 8.2. Exposure controls

### 8.2.1. Engineering controls

Use general dilution ventilation and/or local exhaust ventilation to control airborne exposures to below relevant Exposure Limits and/or control dust/fume/gas/mist/vapors/spray. If ventilation is not adequate, use respiratory protection equipment.

### 8.2.2. Personal protective equipment (PPE)

#### Eye/face protection

Select and use eye/face protection to prevent contact based on the results of an exposure assessment. The following eye/face protection(s) are recommended:

Safety Glasses with side shields  
 Indirect Vented Goggles

#### Skin/hand protection

Select and use gloves and/or protective clothing approved to relevant local standards to prevent skin contact based on the results of an exposure assessment. Selection should be based on use factors such as exposure levels, concentration of the substance or mixture, frequency and duration, physical challenges such as temperature extremes, and other use conditions. Consult with your glove and/or protective clothing manufacturer for selection of appropriate compatible gloves/protective clothing. Note: Nitrile gloves may be worn over polymer laminate gloves to improve dexterity.

Gloves made from the following material(s) are recommended: Polymer laminate

If this product is used in a manner that presents a higher potential for exposure (e.g., spraying, high splash potential, etc.), then use of a protective apron may be necessary. See recommended glove material(s) for determining appropriate apron material(s). If a glove material is not available as an apron, polymer laminate is a suitable option.

#### Respiratory protection

An exposure assessment may be needed to decide if a respirator is required. If a respirator is needed, use respirators as part of a full respiratory protection program. Based on the results of the exposure assessment, select from the following respirator type(s) to reduce inhalation exposure:

Half facepiece or full facepiece air-purifying respirator suitable for organic vapors and particulates  
 Half facepiece or full facepiece supplied-air respirator

For questions about suitability for a specific application, consult with your respirator manufacturer.

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

|                         |                   |
|-------------------------|-------------------|
| Physical state          | Liquid            |
| Specific Physical Form: | Liquid            |
| Color                   | Orange            |
| Odor                    | Slight Acrylate   |
| Odor threshold          | No Data Available |
| pH                      | Not Applicable    |

|                                         |                                                  |
|-----------------------------------------|--------------------------------------------------|
| Melting point                           | <i>Not Applicable</i>                            |
| Boiling Point                           | > 300 °F                                         |
| Flash Point                             | > 200 °F [Test Method:Pensky-Martens Closed Cup] |
| Evaporation rate                        | < 1 [Ref Std:BUOAC=1]                            |
| Flammability                            | Not Applicable                                   |
| Flammable Limits(LEL)                   | <i>No Data Available</i>                         |
| Flammable Limits(UEL)                   | <i>No Data Available</i>                         |
| Vapor Pressure                          | < 1.2 mmHg [@ 20 °C]                             |
| Relative Vapor Density                  | <i>No Data Available</i>                         |
| Density                                 | Approximately 1.3 g/ml                           |
| Relative Density                        | Approximately 1.3 [Ref Std:WATER=1]              |
| Solubility in Water                     | Negligible                                       |
| Solubility- non-water                   | <i>No Data Available</i>                         |
| Partition coefficient: n-octanol/ water | <i>No Data Available</i>                         |
| Autoignition temperature                | <i>No Data Available</i>                         |
| Decomposition temperature               | <i>No Data Available</i>                         |
| Kinematic Viscosity                     | <i>No Data Available</i>                         |
| Volatile Organic Compounds              | 7 g/l                                            |
| Percent volatile                        | 1 - 5 % weight                                   |
| VOC Less H2O & Exempt Solvents          | 7 g/l                                            |
| Particle Characteristics                | <i>Not Applicable</i>                            |

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

This material may be reactive with certain agents under certain conditions - see the remaining headings in this section.

### 10.2. Chemical stability

Stable.

### 10.3. Possibility of hazardous reactions

Hazardous polymerization may occur. Upon loss of initiator or with exposure to heat.

### 10.4. Conditions to avoid

Sparks and/or flames

Heat

### 10.5. Incompatible materials

Strong oxidizing agents

### 10.6. Hazardous decomposition products

| <u>Substance</u> | <u>Condition</u> |
|------------------|------------------|
| None known.      |                  |

Refer to section 5.2 for hazardous decomposition products during combustion.

## SECTION 11: Toxicological information

The information below may not be consistent with the material classification in Section 2 if specific ingredient classifications are mandated by a competent authority. In addition, toxicological data on ingredients may not be reflected in the material classification and/or the signs and symptoms of exposure, because an ingredient may be present below the threshold for labeling, an ingredient may not be available for exposure, or the data may not be relevant to the material as a whole.

## 11.1. Information on Toxicological effects

### Signs and Symptoms of Exposure

Based on test data and/or information on the components, this material may produce the following health effects:

#### Inhalation:

Respiratory Tract Irritation: Signs/symptoms may include cough, sneezing, nasal discharge, headache, hoarseness, and nose and throat pain. May cause additional health effects (see below).

#### Skin Contact:

Mild Skin Irritation: Signs/symptoms may include localized redness, swelling, itching, and dryness. Allergic Skin Reaction (non-photo induced): Signs/symptoms may include redness, swelling, blistering, and itching.

#### Eye Contact:

Severe Eye Irritation: Signs/symptoms may include significant redness, swelling, pain, tearing, cloudy appearance of the cornea, and impaired vision.

#### Ingestion:

May be harmful if swallowed. Gastrointestinal Irritation: Signs/symptoms may include abdominal pain, stomach upset, nausea, vomiting and diarrhea. May cause additional health effects (see below).

### Additional Health Effects:

#### Prolonged or repeated exposure may cause target organ effects:

Respiratory Effects: Signs/symptoms may include cough, shortness of breath, chest tightness, wheezing, increased heart rate, bluish colored skin (cyanosis), sputum production, changes in lung function tests, and/or respiratory failure.

#### Reproductive/Developmental Toxicity:

Contains a chemical or chemicals which can cause birth defects or other reproductive harm.

### Toxicological Data

If a component is disclosed in section 3 but does not appear in a table below, either no data are available for that endpoint or the data are not sufficient for classification.

#### Acute Toxicity

| Name                                                                        | Route     | Species                | Value                                                   |
|-----------------------------------------------------------------------------|-----------|------------------------|---------------------------------------------------------|
| Overall product                                                             | Dermal    |                        | No data available; calculated ATE >5,000 mg/kg          |
| Overall product                                                             | Ingestion |                        | No data available; calculated ATE >2,000 - =5,000 mg/kg |
| PHENOXY ETHYL ACRYLATE                                                      | Dermal    | Rat                    | LD50 > 2,000 mg/kg                                      |
| PHENOXY ETHYL ACRYLATE                                                      | Ingestion | Rat                    | LD50 > 5,000 mg/kg                                      |
| METHACRYLATE POLYMER                                                        | Dermal    |                        | LD50 estimated to be > 5,000 mg/kg                      |
| METHACRYLATE POLYMER                                                        | Ingestion |                        | LD50 estimated to be 2,000 - 5,000 mg/kg                |
| VINYLCAPROLACTAM                                                            | Dermal    | Rabbit                 | LD50 1,700 mg/kg                                        |
| VINYLCAPROLACTAM                                                            | Ingestion | Rat                    | LD50 1,049 mg/kg                                        |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE          | Ingestion | Rat                    | LD50 > 2,000 mg/kg                                      |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE          | Dermal    | similar health hazards | LD50 estimated to be > 5,000 mg/kg                      |
| DIETHYLENE GLYCOL ETHYL ETHER ACRYLATE                                      | Dermal    |                        | LD50 estimated to be 1,000 - 2,000 mg/kg                |
| DIETHYLENE GLYCOL ETHYL ETHER ACRYLATE                                      | Ingestion | Rat                    | LD50 1,860 mg/kg                                        |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Dermal    | Rat                    | LD50 > 2,000 mg/kg                                      |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion | Rat                    | LD50 > 5,000 mg/kg                                      |

|                                                                                 |                                |        |                    |
|---------------------------------------------------------------------------------|--------------------------------|--------|--------------------|
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-               | Dermal                         | Rat    | LD50 > 2,000 mg/kg |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-               | Ingestion                      | Rat    | LD50 967 mg/kg     |
| 2-PHENOXYETHANOL                                                                | Dermal                         | Rabbit | LD50 > 2,000 mg/kg |
| 2-PHENOXYETHANOL                                                                | Inhalation-Dust/Mist           | Rat    | LC50 > 1.5 mg/l    |
| 2-PHENOXYETHANOL                                                                | Ingestion                      | Rat    | LD50 1,394 mg/kg   |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Dermal                         | Rabbit | LD50 > 2,000 mg/kg |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Ingestion                      | Rat    | LD50 > 2,000 mg/kg |
| OCTAMETHYLCYCLOTETRASIOXANE                                                     | Dermal                         | Rat    | LD50 > 2,400 mg/kg |
| OCTAMETHYLCYCLOTETRASIOXANE                                                     | Inhalation-Dust/Mist (4 hours) | Rat    | LC50 36 mg/l       |
| OCTAMETHYLCYCLOTETRASIOXANE                                                     | Ingestion                      | Rat    | LD50 > 4,800 mg/kg |

ATE = acute toxicity estimate

### Skin Corrosion/Irritation

| Name                                                                            | Species | Value                     |
|---------------------------------------------------------------------------------|---------|---------------------------|
| PHENOXY ETHYL ACRYLATE                                                          | Rabbit  | No significant irritation |
| VINYLCAPROLACTAM                                                                | Rabbit  | Minimal irritation        |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE              | Rabbit  | No significant irritation |
| DIETHYLENE GLYCOL ETHYL ETHER ACRYLATE                                          | Rabbit  | Irritant                  |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-     | Rabbit  | No significant irritation |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-               | Rabbit  | No significant irritation |
| 2-PHENOXYETHANOL                                                                | Rabbit  | No significant irritation |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Rabbit  | Minimal irritation        |
| OCTAMETHYLCYCLOTETRASIOXANE                                                     | Rabbit  | No significant irritation |

### Serious Eye Damage/Irritation

| Name                                                                            | Species | Value                     |
|---------------------------------------------------------------------------------|---------|---------------------------|
| PHENOXY ETHYL ACRYLATE                                                          | Rabbit  | No significant irritation |
| VINYLCAPROLACTAM                                                                | Rabbit  | Severe irritant           |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE              | Rabbit  | No significant irritation |
| DIETHYLENE GLYCOL ETHYL ETHER ACRYLATE                                          | Rabbit  | Severe irritant           |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-     | Rabbit  | No significant irritation |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-               | Rabbit  | No significant irritation |
| 2-PHENOXYETHANOL                                                                | Rabbit  | Corrosive                 |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Rabbit  | Severe irritant           |
| OCTAMETHYLCYCLOTETRASIOXANE                                                     | Rabbit  | No significant irritation |

### Skin Sensitization

| Name                                                               | Species    | Value          |
|--------------------------------------------------------------------|------------|----------------|
| PHENOXY ETHYL ACRYLATE                                             | Guinea pig | Sensitizing    |
| VINYLCAPROLACTAM                                                   | Mouse      | Sensitizing    |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE | Mouse      | Not classified |
| DIETHYLENE GLYCOL ETHYL ETHER ACRYLATE                             | Guinea pig | Sensitizing    |

|                                                                                 |                  |                |
|---------------------------------------------------------------------------------|------------------|----------------|
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-     | Guinea pig       | Not classified |
| 2-PHENOXYETHANOL                                                                | Guinea pig       | Not classified |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Mouse            | Sensitizing    |
| OCTAMETHYLCYCLOTETRASILOXANE                                                    | Human and animal | Not classified |

### Respiratory Sensitization

For the component/components, either no data are currently available or the data are not sufficient for classification.

### Germ Cell Mutagenicity

| Name                                                                            | Route    | Value                                                                        |
|---------------------------------------------------------------------------------|----------|------------------------------------------------------------------------------|
| VINYLCAPROLACTAM                                                                | In Vitro | Not mutagenic                                                                |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLINE-8,17-DIONE              | In Vitro | Not mutagenic                                                                |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-     | In Vitro | Not mutagenic                                                                |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-     | In vivo  | Not mutagenic                                                                |
| 2-PHENOXYETHANOL                                                                | In Vitro | Not mutagenic                                                                |
| 2-PHENOXYETHANOL                                                                | In vivo  | Not mutagenic                                                                |
| .ALPHA.,.ALPHA.',.ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | In Vitro | Some positive data exist, but the data are not sufficient for classification |
| OCTAMETHYLCYCLOTETRASILOXANE                                                    | In vivo  | Not mutagenic                                                                |
| OCTAMETHYLCYCLOTETRASILOXANE                                                    | In Vitro | Some positive data exist, but the data are not sufficient for classification |

### Carcinogenicity

| Name                         | Route      | Species                 | Value                                                                        |
|------------------------------|------------|-------------------------|------------------------------------------------------------------------------|
| 2-PHENOXYETHANOL             | Ingestion  | Multiple animal species | Not carcinogenic                                                             |
| OCTAMETHYLCYCLOTETRASILOXANE | Inhalation | Rat                     | Some positive data exist, but the data are not sufficient for classification |

### Reproductive Toxicity

#### Reproductive and/or Developmental Effects

| Name                                                                        | Route     | Value                                  | Species | Test Result           | Exposure Duration        |
|-----------------------------------------------------------------------------|-----------|----------------------------------------|---------|-----------------------|--------------------------|
| PHENOXY ETHYL ACRYLATE                                                      | Ingestion | Not classified for male reproduction   | Rat     | NOAEL 800 mg/kg/day   | 43 days                  |
| PHENOXY ETHYL ACRYLATE                                                      | Ingestion | Toxic to female reproduction           | Rat     | NOAEL 300 mg/kg/day   | premating into lactation |
| PHENOXY ETHYL ACRYLATE                                                      | Ingestion | Toxic to development                   | Rat     | NOAEL 300 mg/kg/day   | premating into lactation |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLIN E-8,17-DIONE         | Ingestion | Not classified for female reproduction | Rat     | NOAEL 1,000 mg/kg/day | premating into lactation |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLIN E-8,17-DIONE         | Ingestion | Not classified for male reproduction   | Rat     | NOAEL 1,000 mg/kg/day | 28 days                  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHENANTHROLIN E-8,17-DIONE         | Ingestion | Not classified for development         | Rat     | NOAEL 1,000 mg/kg/day | premating into lactation |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion | Not classified for female reproduction | Rat     | NOAEL 300 mg/kg/day   | 1 generation             |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-                | Ingestion | Not classified for male reproduction   | Rat     | NOAEL 300 mg/kg/day   | 1 generation             |

|                                                                                   |            |                                        |        |                       |                          |
|-----------------------------------------------------------------------------------|------------|----------------------------------------|--------|-----------------------|--------------------------|
| (PHENYLMETHYL)-                                                                   |            |                                        |        |                       |                          |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)-       | Ingestion  | Toxic to development                   | Rat    | NOAEL 30 mg/kg/day    | 1 generation             |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-                 | Ingestion  | Toxic to female reproduction           | Rat    | LOAEL 40 mg/kg/day    | 1 generation             |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-                 | Ingestion  | Toxic to development                   | Rat    | LOAEL 40 mg/kg/day    | 1 generation             |
| 2-PHENOXYETHANOL                                                                  | Ingestion  | Not classified for female reproduction | Mouse  | NOAEL 3,700 mg/kg/day | 2 generation             |
| 2-PHENOXYETHANOL                                                                  | Ingestion  | Not classified for male reproduction   | Mouse  | NOAEL 3,700 mg/kg/day | 2 generation             |
| 2-PHENOXYETHANOL                                                                  | Dermal     | Not classified for development         | Rabbit | NOAEL 600 mg/kg/day   | during organogenesis     |
| 2-PHENOXYETHANOL                                                                  | Ingestion  | Not classified for development         | Rat    | NOAEL 1,000 mg/kg/day | during gestation         |
| .ALPHA.,..ALPHA.',..ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Ingestion  | Not classified for female reproduction | Rat    | NOAEL 750 mg/kg/day   | premating into lactation |
| .ALPHA.,..ALPHA.',..ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Ingestion  | Not classified for male reproduction   | Rat    | NOAEL 750 mg/kg/day   | 29 days                  |
| .ALPHA.,..ALPHA.',..ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Ingestion  | Not classified for development         | Rat    | NOAEL 1,000 mg/kg/day | during organogenesis     |
| OCTAMETHYLCYCLOTETRASIOXANE                                                       | Inhalation | Not classified for male reproduction   | Rat    | NOAEL 8.5 mg/l        | 2 generation             |
| OCTAMETHYLCYCLOTETRASIOXANE                                                       | Inhalation | Not classified for development         | Rabbit | NOAEL 6 mg/l          | during organogenesis     |
| OCTAMETHYLCYCLOTETRASIOXANE                                                       | Ingestion  | Not classified for development         | Rabbit | NOAEL 100 mg/kg       | during organogenesis     |
| OCTAMETHYLCYCLOTETRASIOXANE                                                       | Inhalation | Toxic to female reproduction           | Rat    | NOAEL 3.6 mg/l        | 2 generation             |

### Target Organ(s)

#### Specific Target Organ Toxicity - single exposure

| Name                                                                              | Route      | Target Organ(s)        | Value                                                                        | Species                 | Test Result         | Exposure Duration |
|-----------------------------------------------------------------------------------|------------|------------------------|------------------------------------------------------------------------------|-------------------------|---------------------|-------------------|
| VINYLCAPROLACTAM                                                                  | Inhalation | respiratory irritation | Some positive data exist, but the data are not sufficient for classification | Rat                     | NOAEL Not available |                   |
| 2-PHENOXYETHANOL                                                                  | Inhalation | respiratory irritation | May cause respiratory irritation                                             | official classification | NOAEL Not available |                   |
| .ALPHA.,..ALPHA.',..ALPHA."-1,2,3-PROPANETRIYLTRIS[POLYPROPYLENE GLYCOL ACRYLATE] | Inhalation | respiratory irritation | Some positive data exist, but the data are not sufficient for classification | similar health hazards  | NOAEL Not available |                   |

#### Specific Target Organ Toxicity - repeated exposure

| Name             | Route      | Target Organ(s)    | Value                                                          | Species | Test Result      | Exposure Duration |
|------------------|------------|--------------------|----------------------------------------------------------------|---------|------------------|-------------------|
| VINYLCAPROLACTAM | Inhalation | respiratory system | Causes damage to organs through prolonged or repeated exposure | Rat     | NOAEL 0.001 mg/l | 28 days           |
| VINYLCAPROLACTAM | Inhalation | blood              | Not classified                                                 | Rat     | NOAEL 0.18 mg/l  | 90 days           |
| VINYLCAPROLACTAM | Inhalation | liver              | Not classified                                                 | Rat     | NOAEL 0.18 mg/l  | 90 days           |
| VINYLCAPROLACTAM | Inhalation | kidney and/or      | Not classified                                                 | Rat     | NOAEL 0.18 mg/l  | 90 days           |

|                                                                             |            |                           |                                                                              |     |                       |          |
|-----------------------------------------------------------------------------|------------|---------------------------|------------------------------------------------------------------------------|-----|-----------------------|----------|
|                                                                             |            | bladder                   |                                                                              |     | mg/l                  |          |
| VINYLCAPROLACTAM                                                            | Inhalation | eyes                      | Not classified                                                               | Rat | NOAEL 0.18 mg/l       | 90 days  |
| VINYLCAPROLACTAM                                                            | Ingestion  | liver                     | Not classified                                                               | Rat | NOAEL 260 mg/kg/day   | 3 months |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | respiratory system        | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | endocrine system          | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | hematopoietic system      | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | nervous system            | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | eyes                      | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| BENZIMIDAZO[2,1-B:2',1'-I]BENZO[LMN][3,8]PHE NANTHROLINE-8,17-DIONE         | Ingestion  | kidney and/or bladder     | Not classified                                                               | Rat | NOAEL 1,000 mg/kg/day | 28 days  |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion  | endocrine system          | Not classified                                                               | Rat | NOAEL 500 mg/kg/day   | 28 days  |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion  | hematopoietic system      | Not classified                                                               | Rat | NOAEL 500 mg/kg/day   | 28 days  |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion  | liver                     | Not classified                                                               | Rat | NOAEL 500 mg/kg/day   | 28 days  |
| 1-BUTANONE, 2-(DIMETHYLAMINO)-1-[4-(4-MORPHOLINYL)PHENYL]-2-(PHENYLMETHYL)- | Ingestion  | kidney and/or bladder     | Not classified                                                               | Rat | NOAEL 500 mg/kg/day   | 28 days  |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-MORPHOLINYL)-           | Ingestion  | peripheral nervous system | Some positive data exist, but the data are not sufficient for classification | Rat | NOAEL 75 mg/kg/day    | 90 days  |
| 1-PROPANONE, 2-METHYL-1-[4-(METHYLTHIO)PHENYL]-2-(4-                        | Ingestion  | eyes                      | Some positive data exist, but the data are not sufficient for classification | Rat | NOAEL 75 mg/kg/day    | 90 days  |

|                                                                                 |           |                       |                |        |                       |          |
|---------------------------------------------------------------------------------|-----------|-----------------------|----------------|--------|-----------------------|----------|
| MORPHOLINYL)-                                                                   |           |                       |                |        |                       |          |
| 2-PHENOXYETHANOL                                                                | Dermal    | skin                  | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Dermal    | hematopoietic system  | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Dermal    | liver                 | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Dermal    | eyes                  | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | heart                 | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | endocrine system      | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | hematopoietic system  | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | liver                 | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | immune system         | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | nervous system        | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | kidney and/or bladder | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| 2-PHENOXYETHANOL                                                                | Ingestion | respiratory system    | Not classified | Rat    | NOAEL 1,514 mg/kg/day | 13 weeks |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | heart                 | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | skin                  | Not classified | Rabbit | LOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | liver                 | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | nervous system        | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | kidney and/or bladder | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Dermal    | respiratory system    | Not classified | Rabbit | NOAEL 500 mg/kg/day   | 2 weeks  |
| .ALPHA.,.ALPHA.',ALPHA."-1,2,3-PROPANETRIYLTRIS[P OLYPROPYLENE GLYCOL ACRYLATE] | Ingestion | liver                 | Not classified | Rat    | NOAEL 750 mg/kg/day   | 29 days  |

|                                                                                                |            |                          |                |        |                             |              |
|------------------------------------------------------------------------------------------------|------------|--------------------------|----------------|--------|-----------------------------|--------------|
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | kidney and/or<br>bladder | Not classified | Rat    | NOAEL 750<br>mg/kg/day      | 29 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | gastrointestinal tract   | Not classified | Rat    | NOAEL 150<br>mg/kg/day      | 90 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | immune system            | Not classified | Rat    | NOAEL 750<br>mg/kg/day      | 29 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | endocrine system         | Not classified | Rat    | NOAEL 375<br>mg/kg/day      | 90 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | hematopoietic<br>system  | Not classified | Rat    | NOAEL 375<br>mg/kg/day      | 90 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | nervous system           | Not classified | Rat    | NOAEL 375<br>mg/kg/day      | 90 days      |
| .ALPHA.,.ALPHA.',.ALP<br>HA."-1,2,3-<br>PROPANETRIYLTRIS[P<br>OLYPROPYLENE<br>GLYCOL ACRYLATE] | Ingestion  | eyes                     | Not classified | Rat    | NOAEL 375<br>mg/kg/day      | 90 days      |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Dermal     | hematopoietic<br>system  | Not classified | Rabbit | NOAEL 960<br>mg/kg/day      | 3 weeks      |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Inhalation | liver                    | Not classified | Rat    | NOAEL 8.5<br>mg/l           | 13 weeks     |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Inhalation | endocrine system         | Not classified | Rat    | NOAEL 8.5<br>mg/l           | 2 generation |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Inhalation | immune system            | Not classified | Rat    | NOAEL 8.5<br>mg/l           | 2 generation |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Inhalation | kidney and/or<br>bladder | Not classified | Rat    | NOAEL 8.5<br>mg/l           | 2 generation |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Inhalation | hematopoietic<br>system  | Not classified | Rat    | NOAEL 8.5<br>mg/l           | 13 weeks     |
| OCTAMETHYLCYCLOT<br>ETRASILOXANE                                                               | Ingestion  | liver                    | Not classified | Rat    | NOAEL<br>1,600<br>mg/kg/day | 2 weeks      |

**Aspiration Hazard**

For the component/components, either no data are currently available or the data are not sufficient for classification.

Please contact the address or phone number listed on the first page of the SDS for additional toxicological information on this material and/or its components.

**SECTION 12: Ecological information****Ecotoxicological information**

Please contact the address or phone number listed on the first page of the SDS for additional ecotoxicological information on this material and/or its components.

**Chemical fate information**

Please contact the address or phone number listed on the first page of the SDS for additional chemical fate information on this material and/or its components.

## SECTION 13: Disposal considerations

### 13.1. Disposal methods

Dispose of contents/ container in accordance with the local/regional/national/international regulations.

Dispose of waste product in a permitted industrial waste facility. As a disposal alternative, incinerate in a permitted waste incineration facility. Proper destruction may require the use of additional fuel during incineration processes. Empty drums/barrels/containers used for transporting and handling hazardous chemicals (chemical substances/mixtures/preparations classified as Hazardous as per applicable regulations) shall be considered, stored, treated & disposed of as hazardous wastes unless otherwise defined by applicable waste regulations. Consult with the respective regulating authorities to determine the available treatment and disposal facilities.

EPA Hazardous Waste Number (RCRA): Not regulated

## SECTION 14: Transport Information

For Transport Information, please visit <http://3M.com/Transportinfo> or call 1-800-364-3577 or 651-737-6501.

## SECTION 15: Regulatory information

### 15.1. US Federal Regulations

Contact 3M for more information.

#### EPCRA 311/312 Hazard Classifications:

##### Physical Hazards

Not Applicable.

##### Health Hazards

Reproductive toxicity

Respiratory or Skin Sensitization

Serious eye damage or eye irritation

Specific target organ toxicity (single or repeated exposure)

Section 313 Toxic Chemicals subject to the reporting requirements of that section and 40 CFR part 372 (EPCRA):

#### Ingredient

2-PHENOXYETHANOL

#### C.A.S. No

122-99-6

#### % by Wt

Trade Secret 0.5 - 1.5

### 15.2. State Regulations

Contact 3M for more information.

### 15.3. Chemical Inventories

The components of this product are in compliance with the chemical notification requirements of TSCA. All required components of this product are listed on the active portion of the TSCA Inventory.

Contact 3M for more information.

## 15.4. International Regulations

Contact 3M for more information.

This SDS has been prepared to meet the U.S. OSHA Hazard Communication Standard, 29 CFR 1910.1200.

## SECTION 16: Other information

### NFPA Hazard Classification

Health: 2 Flammability: 1 Instability: 0 Special Hazards: None

National Fire Protection Association (NFPA) hazard ratings are designed for use by emergency response personnel to address the hazards that are presented by short-term, acute exposure to a material under conditions of fire, spill, or similar emergencies. Hazard ratings are primarily based on the inherent physical and toxic properties of the material but also include the toxic properties of combustion or decomposition products that are known to be generated in significant quantities.

|                        |           |                         |          |
|------------------------|-----------|-------------------------|----------|
| <b>Document Group:</b> | 20-7261-9 | <b>Version Number:</b>  | 8.01     |
| <b>Issue Date:</b>     | 07/17/26  | <b>Supersedes Date:</b> | 05/30/24 |

DISCLAIMER: The information in this Safety Data Sheet (SDS) is believed to be correct as of the date issued. 3M MAKES NO WARRANTIES, EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR COURSE OF PERFORMANCE OR USAGE OF TRADE. User is responsible for determining whether the 3M product is fit for a particular purpose and suitable for user's method of use or application. Given the variety of factors that can affect the use and application of a 3M product, some of which are uniquely within the user's knowledge and control, it is essential that the user evaluate the 3M product to determine whether it is fit for a particular purpose and suitable for user's method of use or application.

3M provides information in electronic form as a service to its customers. Due to the remote possibility that electronic transfer may have resulted in errors, omissions or alterations in this information, 3M makes no representations as to its completeness or accuracy. In addition, information obtained from a database may not be as current as the information in the SDS available directly from 3M.

3M USA SDSs are available at [www.3M.com](http://www.3M.com)